Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
about
Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitroMicroglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic MiceRole of microRNAs in the Regulation of α-Synuclein Expression: A Systematic ReviewParkinson's disease: animal models and dopaminergic cell vulnerabilityMeeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activationDegradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neuronsBax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's diseaseRepression of alpha-synuclein expression and toxicity by microRNA-7.Neuroanatomical phenotyping in the mouse: the dopaminergic system.Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's diseaseSerine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates.Environment, mitochondria, and Parkinson's disease.Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines.Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease.Regulation of alpha-synuclein expression: implications for Parkinson's disease.Loss of mitochondrial fission depletes axonal mitochondria in midbrain dopamine neurons.Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouseHuman and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element.Neuroprotective effects of protocatechuic aldehyde against neurotoxin-induced cellular and animal models of Parkinson's disease.Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease.Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.A guide to neurotoxic animal models of Parkinson's diseaseThe protective effect of lactoferrin on ventral mesencephalon neurons against MPP + is not connected with its iron binding ability.α-Synuclein levels modulate Huntington's disease in mice.Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in MouseEnhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like miceInteraction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.Icariin reduces α-synuclein over-expression by promoting α-synuclein degradation.Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells.α-Synuclein and nonhuman primate models of Parkinson's diseaseImpact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's diseaseAcupuncture promotes mTOR-independent autophagic clearance of aggregation-prone proteins in mouse brain.Direct α-synuclein promoter transactivation by the tumor suppressor p53.Adenosine monophosphate-activated protein kinase overactivation leads to accumulation of α-synuclein oligomers and decrease of neurites.
P2860
Q24311461-FC77B620-A656-4EBF-BB43-E677E6EEF6E2Q26773064-D3A4A3C1-0F07-4050-9D01-BD82A6268E5BQ28080047-74AEEE8C-D6B8-44AE-BD9D-42545AD35737Q28080503-56D14E38-0759-41D9-9B1F-401AF346C3D0Q28387116-E5E2E8E0-985E-43A8-B01D-73A4683256F1Q28477043-2ADD7AB6-5154-466E-A111-3D8FB10C0EB0Q28511388-F4104C9F-97A0-4B8B-9761-9A425F4CC426Q28594269-A8C4F4D4-7E42-4316-848F-AA3119176EF7Q29542272-DD99B6EE-1857-477A-BC5D-91E4CCD8A61AQ33227606-13AB5A89-E006-4635-9691-D885B9D57D86Q33323265-4AA38BC2-3CDC-4408-9D51-D747AC808F2BQ33837238-A1758B96-DD4D-4864-BBB9-34DDBE0E261CQ33843073-8D061C9A-5B30-4085-AA72-65EA1E5ADB1CQ33850971-31C070B5-9D3B-4AE6-BD4B-DD65A3808734Q33885205-ECCC1C97-4630-4932-A257-82791E40C47FQ34061568-D88B221F-F8D6-45B9-A2F8-3F1E0F9C7812Q34133031-6030057D-BC0E-4E3B-8448-92EF8B3D678BQ34257471-438B7051-84DE-485E-A003-D1E048823DDEQ34306521-1531B4B2-BFCE-4146-B425-03547F5B2AA5Q34344563-9811E03E-BEC1-4835-89C0-0BD8F219EAD9Q34383447-CA66E81C-E8FA-4823-94CA-28449F20C99DQ34648491-CF79D2B7-3BC6-4D52-873F-09C4FEF376C0Q34714740-458FE1FE-C5D3-4F62-AAEC-95864F495EF5Q35031554-5D4E59D3-EA01-423B-838E-936CF80C4DACQ35036220-C0E66876-A16B-441B-A813-D285B944187BQ35054395-0DE000B0-2B3C-4E4B-94D5-3490D251A8E5Q35058315-1F99ED37-4DBC-4710-B8B3-E9079963952CQ35603488-59A00E5B-37DD-4D35-B749-AB3BC12271E3Q35673103-4091789C-6B5D-4CEB-97BD-5F1A1BAD76DBQ35674687-D39D3AB8-F32D-41C4-AE50-294400B2E92CQ35675406-6CE9ECA9-F64F-4B7A-857D-6B85DBE47C35Q35730391-E0032BCF-8C83-456E-A391-5D8DF9F1DA4CQ35834043-5A32ECE1-6830-433E-9AA8-C2D84C1B222BQ35849000-94C34936-5D0B-4FDA-97A0-97F19368C490Q35850739-917CB560-DA8C-46E7-8908-303B84FC402AQ36157306-05173DE2-DA7B-4A1F-81C2-2FC5E621329EQ36462680-D2953294-97F3-459D-BB6D-372534340EDDQ36501190-6FB29B99-EDC0-40FA-8693-C071D36097E6Q36531366-1E120305-80EE-4C93-BB33-A42530D77C29Q36604979-01688D44-CE61-4EC1-94AE-4C40E4573663
P2860
Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Alpha-synuclein up-regulation ...... f the parkinsonian toxin MPTP.
@en
Alpha-synuclein up-regulation ...... f the parkinsonian toxin MPTP.
@nl
type
label
Alpha-synuclein up-regulation ...... f the parkinsonian toxin MPTP.
@en
Alpha-synuclein up-regulation ...... f the parkinsonian toxin MPTP.
@nl
prefLabel
Alpha-synuclein up-regulation ...... f the parkinsonian toxin MPTP.
@en
Alpha-synuclein up-regulation ...... f the parkinsonian toxin MPTP.
@nl
P2093
P50
P921
P1476
Alpha-synuclein up-regulation ...... f the parkinsonian toxin MPTP.
@en
P2093
P304
P356
10.1046/J.1471-4159.2000.740721.X
P407
P577
2000-02-01T00:00:00Z